Blood Cancer Player Arcellx ' s Lead Product Exceeds Expectations, Analysts Say

Friday, Arcellx Inc ACLX announced new data from its Phase 1 expansion study of CART-ddBCMA, now known as anitocabtagene autoleucel (anito-cel) for relapsed and/or refractory multiple myeloma. The interim anito-cel Phase 1 clinical results (October 15, 2023 cutoff date) demonstrate deep and…#arcellxincaclx #phase1 #median #williamblair #aclx
Source: Reuters: Health - Category: Consumer Health News Source Type: news